Xellia Pharmaceuticals ApS-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Xellia Pharmaceuticals ApS - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013485
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月28日
◆ページ数:26
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:デンマーク
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Xellia Pharmaceuticals ApS (Xellia), a subsidiary of Novo A/S is a healthcare products provider that offers fermented and semi-synthetic APIs and injectable finished dosage forms. The company offers strain and fermentation development with bacteria and fungi. It provides injectable products in the form of liquids, aseptically filled dry powders or in the form of freeze-dried powders; and inhalable products. Xellia offers products in therapeutic areas including gram-negative infections, gram-positive infections, resistance scare in healthcare, pathogenic microorganisms and fungal infections. The company operates manufacturing facilities in Denmark, the US, Hungary and China. Xellia is headquartered in Copenhagen, Denmark.

Xellia Pharmaceuticals ApS – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Xellia Pharmaceuticals ApS, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Xellia Pharmaceuticals ApS, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Xellia Pharmaceuticals ApS, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Xellia Pharmaceuticals ApS, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Xellia Pharmaceuticals ApS, Medical Devices Deals, 2011 to YTD 2017 9
Xellia Pharmaceuticals ApS, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Xellia Pharmaceuticals ApS, Pharmaceuticals & Healthcare, Deal Details 11
Asset Purchase 11
Xellia Acquires Lyophilized Manufacturing Facility from Fresenius Kabi 11
Partnerships 12
Xellia Pharma, SINTEF Materials And Statens Serum Institut Enter Into Agreement To Develop New Antibiotics 12
Acquisition 13
Novo Acquires Xellia Pharma for USD700 Million 13
Xellia Pharmaceuticals ApS – Key Competitors 15
Xellia Pharmaceuticals ApS – Key Employees 16
Xellia Pharmaceuticals ApS – Locations And Subsidiaries 17
Head Office 17
Other Locations & Subsidiaries 17
Joint Venture 17
Recent Developments 18
Strategy And Business Planning 18
Oct 11, 2017: Xellia Pharmaceuticals Expands its Global Specialty Anti-infective Product Manufacturing Capabilities with a US$25m Investment in its Copenhagen Site 18
Aug 22, 2017: Xellia Pharmaceuticals Completes Expansion of its Budapest Facilities, Strengthening its Global Anti-infective Product Capabilities 19
May 25, 2016: Xellia Pharmaceuticals Expands Budapest Facilities to Strengthen Anti-infective Product Capabilities 20
Financial Announcements 21
Apr 29, 2016: Xellia Pharmaceuticals Full Year Results for the year ended 31 December 2015 21
Legal and Regulatory 22
Nov 14, 2016: Xellia Pharmaceuticals Commences Packaging and Distribution Operations at Cleveland Site after Successful FDA Inspection 22
Apr 25, 2016: Xellia Pharmaceuticals Reaches Agreement with FDA on Modifications to Consent Decree for Newly-Acquired Cleveland Site 23
Product News 24
Sep 27, 2016: Xellia Pharmaceuticals Expands Croatian Anti-Infective Product and Innovation Capabilities to Tackle Antimicrobial Resistance Crisis 24
Other Significant Developments 25
Jan 18, 2017: Xellia Pharmaceuticals Signs Davos Declaration on Combating Antimicrobial Resistance 25
Appendix 26
Methodology 26
About GlobalData 26
Contact Us 26
Disclaimer 26

List of Tables
Xellia Pharmaceuticals ApS, Pharmaceuticals & Healthcare, Key Facts 2
Xellia Pharmaceuticals ApS, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Xellia Pharmaceuticals ApS, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Xellia Pharmaceuticals ApS, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Xellia Pharmaceuticals ApS, Deals By Therapy Area, 2011 to YTD 2017 8
Xellia Pharmaceuticals ApS, Medical Devices Deals, 2011 to YTD 2017 9
Xellia Pharmaceuticals ApS, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Xellia Acquires Lyophilized Manufacturing Facility from Fresenius Kabi 11
Xellia Pharma, SINTEF Materials And Statens Serum Institut Enter Into Agreement To Develop New Antibiotics 12
Novo Acquires Xellia Pharma for USD700 Million 13
Xellia Pharmaceuticals ApS, Key Competitors 15
Xellia Pharmaceuticals ApS, Key Employees 16
Xellia Pharmaceuticals ApS, Subsidiaries 17
Xellia Pharmaceuticals ApS, Joint Venture 17

★海外企業調査レポート[Xellia Pharmaceuticals ApS-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • ProQR Therapeutics NV (PRQR):企業の財務・戦略的SWOT分析
    Summary ProQR Therapeutics NV (ProQR) is a clinical-stage biotech company that discovers and develops drugs for the treatment of genetic disorders. The company’s lead product candidate includes QR-010, a RNA-based oligonucleotide used for the treatment of cystic fibrosis; QR-110, an oligonucleotide …
  • Planet Gas Ltd (PGS):企業の財務・戦略的SWOT分析
    Summary Planet Gas Ltd (Planet Gas) is an upstream oil and gas company that offers acquisition, exploration, production and development of oil and gas properties in the US. The company holds interests in conventional and unconventional oil and gas projects in Australia. It projects explores for coal …
  • MEG Energy Corp (MEG):石油・ガス:M&Aディール及び事業提携情報
    Summary MEG Energy Corp (MEG) is an oil and gas company that develops and produces from oil sands. The company operates Christina lake, May River and Surmont project. Its technologies comprise steam-assisted gravity drainage, cogeneration, Hi-Q field pilot and eMSAGP. MEG's Christina Lake project is …
  • Lab21 Ltd:医療機器:M&Aディール及び事業提携情報
    Summary Lab21 Ltd (Lab21), a subsidiary of Novacyt SA, is a clinical laboratory that offers clinical diagnostic testing services. The company develops molecular diagnostics for oncology and virology. Its oncology includes KRAS, EGFR, BRAF, ALK, RAS-RAF, BRCA, prostate cancer, among others. Lab21’s v …
  • Assurant, Inc.:企業の戦略・SWOT・財務情報
    Assurant, Inc. - Strategy, SWOT and Corporate Finance Report Summary Assurant, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • Swift Biosciences Inc-医療機器分野:企業M&A・提携分析
    Summary Swift Biosciences Inc (Swift Biosciences) is a biotechnology company that develops novel research reagents, protocols, and molecular diagnostic tools. The company offers products such as 2S DNA library kit, 2S plus DNA library kit, 2S PCR-free DNA library kit, methyl-seq DNA library kit, DNA …
  • DexCom Inc (DXCM):企業の製品パイプライン分析
    Summary Dexcom Inc (Dexcom) is a medical device company that designs, develops and commercializes continuous glucose monitoring (CGM) systems. The company’s major products include integrated CGM systems for adults and pediatric use, Dexcom G5 mobile CGM system, Dexcom G4 PLATINUM CGM system, associa …
  • KFG Resources Ltd (KFG):企業の財務・戦略的SWOT分析
    Summary KFG Resources Ltd (KFG) is a petroleum and natural gas exploration company that supplies natural gas. The company produces crude oil and natural gas through its reserves. Its oil and gas reserves are located in Mississippi, Wilcox, and Louisiana. KFG’s Mississippi’s projects comprise Carthag …
  • athenahealth Inc (ATHN):製薬・医療:M&Aディール及び事業提携情報
    Summary athenahealth Inc (athenahealth) is a provider of cloud-based business services and mobile applications for medical groups and health system. The company offers network-enabled services for revenue cycle management and medical billing, electronic health records (EHR), patient engagement, popu …
  • ElectroCore Inc (ECOR):医療機器:M&Aディール及び事業提携情報
    Summary ElectroCore Inc (ElectroCore) is a bioelectronic medicine healthcare company. The company engaged in developing vagus nerve stimulation non-invasively (nVNS) therapy for neurology and rheumatology. It primarily focused on headache such as episodic cluster headache, migraine, and posttraumati …
  • Banesco Banco Universal C.A.:企業の戦略・SWOT・財務情報
    Banesco Banco Universal C.A. - Strategy, SWOT and Corporate Finance Report Summary Banesco Banco Universal C.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • Medusa Mining Ltd:企業の戦略・SWOT・財務情報
    Medusa Mining Ltd - Strategy, SWOT and Corporate Finance Report Summary Medusa Mining Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Campanile UK Ltd:企業の戦略・SWOT・財務分析
    Campanile UK Ltd - Strategy, SWOT and Corporate Finance Report Summary Campanile UK Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Nipro Corp (8086):医療機器:M&Aディール及び事業提携情報
    Summary Nipro Corp (Nipro) manufactures, develops and markets pharmaceuticals, medical equipment and functional materials (including glass, rubber and plastic). The company’s products include renal products, interventional and anesthesiology products, injection and infusion products, cardiopulmonary …
  • Codere S.A.:企業の戦略・SWOT・財務情報
    Codere S.A. - Strategy, SWOT and Corporate Finance Report Summary Codere S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • The Dow Chemical Co (DOW)-石油・ガス分野:企業M&A・提携分析
    Summary The Dow Chemical Company (Dow) is a diversified chemical company. Its businesses encompass specialty chemicals, advanced materials, agrosciences and plastics. The company manufactures and supplies products used primarily as raw materials in the manufacture of customer products and services. …
  • Heron Therapeutics Inc (HRTX):企業の財務・戦略的SWOT分析
    Heron Therapeutics Inc (HRTX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • HEICO Corporation:企業の戦略・SWOT・財務情報
    HEICO Corporation - Strategy, SWOT and Corporate Finance Report Summary HEICO Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Maxim Power Corp. (MXG):電力:M&Aディール及び事業提携情報
    Summary Maxim Power Corp. (Maxim) is an independent power producing corporation that acquires, develops, owns and operates power generation facilities and sells electricity and heat. The corporation generates electricity using various fuel sources including coal, natural gas, and wind, nuclear, hydr …
  • Cardiac Science Corp:企業の戦略的SWOT分析
    Cardiac Science Corp - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and s …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆